Jade Biosciences, Inc. (JBIO) – What Are Brokerages Saying About This Stock?

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO – Get Free Report) have received a consensus rating of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $51.00.

A number of research firms have recently weighed in on JBIO. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price target on shares of Jade Biosciences in a report on Tuesday, August 11th. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Jade Biosciences in a research note on Thursday, October 1st. BTIG Research reissued a “buy” rating on shares of Jade Biosciences in a research report on Monday. Wedbush reissued an “outperform” rating and set a $47.00 target price on shares of Jade Biosciences in a research report on Thursday, October 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Jade Biosciences in a research note on Friday, September 11th.

Check Out Our Latest Report on Jade Biosciences

Jade Biosciences Stock Performance

Shares of NASDAQ JBIO opened at $15.31 on Friday. Jade Biosciences has a 1-year low of $11.02 and a 1-year high of $28.00. The business has a fifty day moving average price of $14.95 and a 200 day moving average price of $18.12.

Jade Biosciences (NASDAQ:JBIO – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.31. On average, research analysts predict that Jade Biosciences will post -2.51 EPS for the current year.

Hedge Funds Weigh In On Jade Biosciences

A number of large investors have recently made changes to their positions in the business. Janus Henderson Group PLC acquired a new position in shares of Jade Biosciences during the first quarter valued at about $43,557,000. Bellevue Group AG raised its position in shares of Jade Biosciences by 40.4% in the 3rd quarter. Bellevue Group AG now owns 4,293,937 shares of the company’s stock valued at $60,330,000 after purchasing an additional 1,235,941 shares during the last quarter. Pictet Asset Management Holding SA raised its position in shares of Jade Biosciences by 64.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,205,972 shares of the company’s stock valued at $16,944,000 after purchasing an additional 472,204 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Jade Biosciences by 22.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 896,834 shares of the company’s stock worth $12,601,000 after purchasing an additional 161,610 shares in the last quarter. Finally, Stempoint Capital LP acquired a new stake in Jade Biosciences in the 1st quarter worth approximately $2,164,000.

About Jade Biosciences

(Get Free Report)

Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.

See Also

Analyst Recommendations for Jade Biosciences (NASDAQ:JBIO)

Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.